Bank of America Corporation (BAC)
Verdict history · BAC
Every call Verdix has made on BAC.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call BAC yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NYSE · Financials / Banks · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitMEDIUM confidence
Why
Six distinct investing frameworks examine Bank of America at $64.49 and reach a rare consensus: the business is excellent, but the price offers no cushion. Every archetype agrees the $55–58 range is where value appears, making this a textbook WAIT on a wonderful company trading at a fair-to-full price.Level to watch
Key resistance 65.2+1.1% from 64.49
Next catalyst
Pullback to the accumulation zone: A 10–15% decline into the $55–58 range — where weekly EMA20, DCF fair value estimates, and the Margin-of-Safety Hunter Number threshold converge — would flip the panel toward broad BUY conviction.The panel's take
Verdict: WAIT · Conviction: MED · Last price: 64.49
Every voice — bull or cautious — agrees BAC is a high-quality business with a wide moat and strong momentum. The split is purely BUY vs WAIT: the bulls (fundamental scout, sentiment scout, The GARP Operator) want to own it, but three of them explicitly prefer a pullback entry; the four cautious voices (technical scout, The Moat Compounder, The Margin-of-Safety Hunter, The Intrinsic-Value Modeler, The Quality Rationalist, The Forensic Skeptic) all frame their objection strictly around price/timing, not business quality. No voice argues the business is deteriorating or that this is a SELL. This is the textbook BUY vs WAIT structure — a wonderful business trading at a fair-to-full price with no margin of safety. WAIT is the correct synthesis, not BALANCED, because price is the single blocker, multiple voices identify the $55–58 zone as the trigger, and there is no genuine business-level disagreement to resolve.
Key levels
Key levels · BAC
USD · as of 2026-08-15Analyst consensus target 64.49 USD · range 64.49–64.49
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Bank of America Corporation past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: BAC's low-cost deposit franchise — over $300 billion earning near-zero interest — is a structural cost advantage that upstarts cannot easily replicate, and management is compounding that moat with aggressive buybacks that have shrunk shares outstanding roughly 12% in two years. Conviction: Conviction is held back because the stock sits within 2% of all-time highs with a weekly RSI of 74, offering no margin of safety on a business whose earnings are inherently cyclical and rate-dependent.
The Margin-of-Safety HunterValue/Quantitative⚫ NeutralMed
Signal: The stock trades at $64.49 against a The Margin-of-Safety Hunter Number of $65.60, leaving a margin of safety of barely 1.7% — far below the 20–30% discount required for a defensive purchase. Conviction: Conviction is suppressed by the bank's inherent leverage: a debt-to-equity ratio exceeding 9x, which, while normal for money-center banks, fundamentally violates conservative balance-sheet principles and makes the enterprise vulnerable to credit-cycle reversals.
The GARP OperatorGrowth (GARP)🟢 BullishMed
Signal: BAC delivers a PEG ratio of 0.60 — a 14.3x P/E against 24% EPS growth — a combination that in any other industry would scream undervaluation, and management is raising NII guidance to the upper end of 6–8% rather than cutting it. Conviction: Conviction is tempered by the recognition that the stock has already run 42% in twelve months, and the 24% EPS growth rate is tied to a cyclical rate tailwind that will not persist indefinitely.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: A DCF using normalized revenue growth of 4% tapering to 2.5% and a 25% net income margin yields a fair value near $58, roughly 10% below the current price, suggesting the market is already pricing in sustained cyclical tailwinds. Conviction: What holds conviction back is the asymmetry: with analyst consensus at 83% Buy and zero Sells, price at all-time highs, and weekly RSI overbought, bad news now has more room to hurt than good news has to help.
The Quality RationalistMental Models/Quality⚫ NeutralMed
Signal: Moynihan's capital allocation has been rational and disciplined — shares outstanding have shrunk roughly 12% in two years, dividends are rising, and there are no empire-building acquisitions — which makes BAC one of the better-run money-center banks. Conviction: Banking is leveraged, cyclical, and regulated — three traits that make earnings inherently less predictable than the kind of business this framework prefers — and the current price offers no discount to compensate for that structural unpredictability.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The TTM operating cash flow of $94.7 billion against net income of $32.1 billion looks reassuring at first glance, but FY2025 operating cash flow was just $12.6 billion against $29.1 billion in net income — a 0.43x ratio that signals lumpy, potentially unsustainable earnings quality. Conviction: The 0.33 PEG ratio is only cheap if the 24% EPS growth rate persists; normalized to a more realistic 10% growth rate, the PEG swells to roughly 1.4x, removing the apparent valuation bargain.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All six archetypes agree BAC is a high-quality business with a genuine competitive moat rooted in its low-cost deposit franchise and scale.
- No archetype argues the business is deteriorating or that BAC merits a SELL — the divergence is strictly between BUY and WAIT.
- Every archetype identifies the $55–58 zone as the range where value and margin of safety converge favorably.
- All archetypes recognize that the current price is at or near all-time highs, with weekly RSI overbought and bullish sentiment nearly unanimous among sell-side analysts.
- Management quality under Brian Moynihan receives consistent, unqualified praise across the panel for disciplined capital allocation and conservative guidance practices.
The real debate
- The GARP Operator sees a 0.60 PEG ratio and argues the stock is mispriced even at current levels, while The Intrinsic-Value Modeler computes a DCF fair value near $58 and says the market is already discounting the bull case.
- The Forensic Skeptic flags the wild swing in operating cash flow (from $12.6B in FY2025 to $94.7B TTM) as a red flag for earnings quality, whereas The Moat Compounder treats the 2.9x cash-flow-to-earnings ratio as reassuring and focuses instead on the durable deposit franchise.
- The Margin-of-Safety Hunter rejects the bank's 9x debt-to-equity structure as incompatible with defensive-investor criteria, while The Quality Rationalist accepts the leverage as normal for banking but still concludes the business is not wonderful enough to warrant a bet at this price.
The question it comes down to: Can BAC's 24% EPS growth and widening deposit moat sustain earnings above current expectations long enough to justify paying within 2% of all-time highs, or does the cyclical rate tailwind fade before the price offers a genuine margin of safety?
The bottom line
- Pullback to the accumulation zone: A 10–15% decline into the $55–58 range — where weekly EMA20, DCF fair value estimates, and the Margin-of-Safety Hunter Number threshold converge — would flip the panel toward broad BUY conviction.
- Breakout to confirm new highs: A high-volume weekly close above $65.20, clearing the all-time high into blue-sky territory with no overhead resistance, would shift the technical scout voices from cautious to constructive.
- Earnings-quality check at Q3: The next quarterly report must show operating cash flow aligning with net income — a repeat of the FY2025 0.43x CFO/NI ratio would confirm the Forensic Skeptic's earnings-quality concern and erode conviction across the panel.
- NII guidance as the linchpin: Any cut to net interest income guidance from the current 6–8% range — whether from rate cuts, loan-growth stalling, or margin compression — would invalidate the cyclical tailwind thesis and could trigger a reassessment toward bearish.
contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in BAC · BAC verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated